TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.

Karama Asleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.